Published in Cancer Res on December 01, 1997
MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res (2000) 9.30
Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF. Oncogene (2011) 2.10
Frequent p16-independent inactivation of p14ARF in human melanoma. J Natl Cancer Inst (2008) 1.78
The regulation of miRNA-211 expression and its role in melanoma cell invasiveness. PLoS One (2010) 1.55
DNA methylation: an alternative pathway to cancer. Ann Surg (2001) 1.24
Adenomatous polyposis coli (APC) gene promoter hypermethylation in primary breast cancers. Br J Cancer (2001) 1.21
Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies. J Transl Med (2010) 1.17
Significant impact of promoter hypermethylation and the 540 C>T polymorphism of CDKN2A in cutaneous melanoma of the vertical growth phase. Am J Pathol (2002) 1.11
Age-related epigenetic drift in the pathogenesis of MDS and AML. Genome Res (2014) 1.08
Aberrant DNA methylation in malignant melanoma. Melanoma Res (2010) 1.04
Deletion at chromosome arm 9p in relation to BRAF/NRAS mutations and prognostic significance for primary melanoma. Genes Chromosomes Cancer (2010) 1.00
Localization of multiple melanoma tumor-suppressor genes on chromosome 11 by use of homozygosity mapping-of-deletions analysis. Am J Hum Genet (2000) 0.97
Circulating DNA microsatellites: molecular determinants of response to biochemotherapy in patients with metastatic melanoma. J Natl Cancer Inst (2004) 0.97
Functional modulation of IGF-binding protein-3 expression in melanoma. J Invest Dermatol (2010) 0.94
Definition of the role of chromosome 9p21 in sporadic melanoma through genetic analysis of primary tumours and their metastases. The Melanoma Cooperative Group. Br J Cancer (2000) 0.91
DNA methylation in promoter region as biomarkers in prostate cancer. Methods Mol Biol (2012) 0.88
Failure in post-transcriptional processing is a possible inactivation mechanism of AP-2alpha in cutaneous melanoma. Br J Cancer (2000) 0.87
Loss of heterozygosity and methylation of p16 in renal cell carcinoma. Urol Res (2003) 0.85
The contribution of large genomic deletions at the CDKN2A locus to the burden of familial melanoma. Br J Cancer (2008) 0.81
Id1 overexpression is independent of repression and epigenetic silencing of tumor suppressor genes in melanoma. Epigenetics (2010) 0.76
Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities. Clin Epigenetics (2017) 0.75
Cellular differentiation, cytidine analogs and DNA methylation. Cell (1980) 10.15
Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science (1990) 8.91
Multiple new phenotypes induced in 10T1/2 and 3T3 cells treated with 5-azacytidine. Cell (1979) 6.47
5-Methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes. Science (1990) 4.80
The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res (1999) 4.74
Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype? Am J Hum Genet (2000) 4.74
Rapid quantitation of methylation differences at specific sites using methylation-sensitive single nucleotide primer extension (Ms-SNuPE). Nucleic Acids Res (1997) 4.65
Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med (1994) 4.34
Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res (1995) 4.28
Southern blot analysis of DNA extracted from formalin-fixed pathology specimens. Cancer Res (1986) 3.95
Increased cell division as a cause of human cancer. Cancer Res (1990) 3.38
5-methylcytosine, gene regulation, and cancer. Adv Cancer Res (1983) 3.27
Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet (1996) 2.96
Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science (1992) 2.89
Inhibition of DNA methylation by 5-aza-2'-deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res (1998) 2.83
Predicting survival using simple clinical variables: a case study in traumatic brain injury. J Neurol Neurosurg Psychiatry (1999) 2.83
Altering gene expression with 5-azacytidine. Cell (1985) 2.79
DNA methylation decreases in aging but not in immortal cells. Science (1983) 2.67
DNA methylation: past, present and future directions. Carcinogenesis (2000) 2.58
Cytosine methylation does not affect binding of transcription factor Sp1. Proc Natl Acad Sci U S A (1988) 2.56
The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53. Mol Cell Biol (1998) 2.53
p16 gene in uncultured tumours. Nature (1994) 2.47
Functional striated muscle cells from non-myoblast precursors following 5-azacytidine treatment. Nature (1977) 2.44
The rate of hydrolytic deamination of 5-methylcytosine in double-stranded DNA. Nucleic Acids Res (1994) 2.37
Role of intracranial pressure monitoring in severely head-injured patients without signs of intracranial hypertension on initial computerized tomography. J Neurosurg (1994) 2.36
Altered chromatin structure associated with methylation-induced gene silencing in cancer cells: correlation of accessibility, methylation, MeCP2 binding and acetylation. Nucleic Acids Res (2001) 2.27
Parental imprinting: potentially active chromatin of the repressed maternal allele of the mouse insulin-like growth factor II (Igf2) gene. Genes Dev (1992) 2.19
A major quantitative-trait locus for mole density is linked to the familial melanoma gene CDKN2A: a maximum-likelihood combined linkage and association analysis in twins and their sibs. Am J Hum Genet (1999) 2.15
Susceptibility of nonpromoter CpG islands to de novo methylation in normal and neoplastic cells. J Natl Cancer Inst (2001) 2.13
Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS. Br J Cancer (2005) 2.13
Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc Natl Acad Sci U S A (1994) 2.09
High frequency mutagenesis by a DNA methyltransferase. Cell (1992) 2.08
Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst (1998) 2.07
Potency of ergometrine in tropical countries. Lancet (1988) 2.05
Impact of an essential drugs programme on availability and rational use of drugs. Lancet (1989) 2.04
Degradation of connective tissue matrices by macrophages. I. Proteolysis of elastin, glycoproteins, and collagen by proteinases isolated from macrophages. J Exp Med (1980) 2.00
Cytoplasmic accumulation of cdc25B phosphatase in mitosis triggers centrosomal microtubule nucleation in HeLa cells. J Cell Sci (1996) 1.99
Mechanism of action of eukaryotic DNA methyltransferase. Use of 5-azacytosine-containing DNA. J Mol Biol (1982) 1.89
A Taq I polymorphism for the human transforming growth factor alpha gene (TGFA). Nucleic Acids Res (1987) 1.88
PAX6 methylation and ectopic expression in human tumor cells. Int J Cancer (2000) 1.87
p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol (1993) 1.85
Cell cycle-specific reactivation of an inactive X-chromosome locus by 5-azadeoxycytidine. Proc Natl Acad Sci U S A (1982) 1.84
Large scale mapping of methylcytosines in CTCF-binding sites in the human H19 promoter and aberrant hypomethylation in human bladder cancer. Hum Mol Genet (2001) 1.83
Phenotypic conversion of cultured mouse embryo cells by aza pyrimidine nucleosides. Dev Biol (1978) 1.76
Ubiquitous and tenacious methylation of the CpG site in codon 248 of the p53 gene may explain its frequent appearance as a mutational hot spot in human cancer. Mol Cell Biol (1994) 1.74
A psychogeriatric survey of old people's homes. Br Med J (Clin Res Ed) (1981) 1.74
Genome scan of schizophrenia. Am J Psychiatry (1998) 1.74
The role of DNA methylation in expression of the p19/p16 locus in human bladder cancer cell lines. Cancer Res (1998) 1.73
Differential mRNA expression of the human DNA methyltransferases (DNMTs) 1, 3a and 3b during the G(0)/G(1) to S phase transition in normal and tumor cells. Nucleic Acids Res (2000) 1.73
Changes in the allelic methylation patterns of c-H-ras-1, insulin and retinoblastoma genes in human development. Dev Suppl (1990) 1.73
DNA methyltransferase levels in tumorigenic and nontumorigenic cells in culture. J Biol Chem (1986) 1.72
Mice lacking the vascular endothelial growth factor-B gene (Vegfb) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia. Circ Res (2000) 1.72
Glycoprotein, elastin, and collagen secretion by rat smooth muscle cells. Proc Natl Acad Sci U S A (1979) 1.71
Hemimethylated duplex DNAs prepared from 5-azacytidine-treated cells. Nucleic Acids Res (1981) 1.70
Inhibition of DNA methylation by chemical carcinogens in vitro. Cell (1983) 1.68
MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations. Am J Hum Genet (2001) 1.67
Allelic losses of chromosomes 9, 11, and 17 in human bladder cancer. Cancer Res (1990) 1.67
Involvement of DNA methylation in human carcinogenesis. Biol Chem (1998) 1.65
Head injury in the elderly. Age Ageing (1986) 1.65
Scar formation after stereotactic vacuum-assisted core biopsy of benign breast lesions. Clin Radiol (2006) 1.60
Destruction of extracellular matrices containing glycoproteins, elastin, and collagen by metastatic human tumor cells. Cancer Res (1980) 1.59
Prescription of oxygen concentrators: adherence to published guidelines. Thorax (1989) 1.57
Metabolism of the reserve polysaccharide of Streptococcus mitis. Some properties of a pullulanase. Biochem J (1968) 1.55
Leptin and the risk of Barrett's oesophagus. Gut (2008) 1.54
Instability of (methyl)ergometrine in tropical climates: an overview. Eur J Obstet Gynecol Reprod Biol (1996) 1.52
Identification and characterization of differentially methylated regions of genomic DNA by methylation-sensitive arbitrarily primed PCR. Cancer Res (1997) 1.51
DNA methylation differences associated with tumor tissues identified by genome scanning analysis. Genomics (1998) 1.51
Contiguous patches of normal human mammary epithelium derived from a single stem cell: implications for breast carcinogenesis. Cancer Res (1996) 1.51
HhaI and HpaII DNA methyltransferases bind DNA mismatches, methylate uracil and block DNA repair. Nucleic Acids Res (1995) 1.50
Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res (1995) 1.50
Zebularine: a new drug for epigenetic therapy. Biochem Soc Trans (2004) 1.49
Direct construction of a chromosome-specific NotI linking library from flow-sorted chromosomes. Nucleic Acids Res (1989) 1.49
Roles of cell division and gene transcription in the methylation of CpG islands. Mol Cell Biol (1999) 1.49
Fibrinolytic activity in a human fibrosarcoma cell line and evidence for the induction of plasminogen activator secretion during tumor formation. Cell (1975) 1.48
DNA methylation and cancer. Cancer Res (1986) 1.47
The CDKN2A (p16) gene and human cancer. Mol Med (1997) 1.46
Mutations in the neurofibromatosis 1 gene in sporadic malignant melanoma cell lines. Nat Genet (1993) 1.45
Gene expression of lung squamous cell carcinoma reflects mode of lymph node involvement. Eur Respir J (2007) 1.43
Genetic and epigenetic aspects of DNA methylation on genome expression, evolution, mutation and carcinogenesis. Carcinogenesis (1997) 1.43
Glasgow Outcome Scale: an inter-rater reliability study. Brain Inj (1993) 1.42
Change in serum hyaluronan: a simple index of short-term drug-induced changes in hepatic sinusoidal perfusion. Gastroenterology (1993) 1.41
Field evaluation of an albendazole intraruminal capsule against benzimidazole-resistant Haemonchus contortus. Vet Rec (1992) 1.40
Initial experience of intramammary prostheses in breast conservation surgery. Eur J Surg Oncol (1999) 1.38
Mutagenic and epigenetic effects of DNA methylation. Mutat Res (1997) 1.38
Ferritinaemia in leukaemia and Hodgkin's disease. Br J Cancer (1973) 1.37
Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma. Am J Pathol (1996) 1.36
p53 and treatment of bladder cancer. Nature (1997) 1.36
Determinants of the utilization of maternal and child health services in Jordan. Int J Epidemiol (1986) 1.35
Variable effects of DNA-synthesis inhibitors upon DNA methylation in mammalian cells. Nucleic Acids Res (1986) 1.34
In vitro correlates of transformation in C3H/10T1/2 clone 8 mouse cells. Cancer Res (1976) 1.33
Changes in phenotypic expression in embryonic and adult cells treated with 5-azacytidine. J Cell Physiol (1982) 1.32
Allele-specific methylation of the human c-Ha-ras-1 gene. Cell (1987) 1.31
Temporal acquistion of enhanced fibrinolytic activity by syrian hamster embryo cells following treatment with benzo(a)pyrene. Cancer Res (1977) 1.31
Early neonatal mortality and cesarean delivery in Mexico City. Am J Obstet Gynecol (1991) 1.31